Skip to main content Skip to main navigation menu Skip to site footer

Mitomycin C, curcumin, and fibrin glue inhibit the cell proliferation and expression of TGF-β in human pterygium fibroblast

  • Muhammad Abdurrauf ,
  • Ferdian Ramadhan ,
  • Nurwasis ,
  • Ismi Zuhria ,
  • Betty Agustina Tambunan ,
  • Hari Basuki Notobroto ,
  • Budi Surahman ,
  • Evelyn Komaratih ,

Abstract

Introduction: High recurrence of a fibrotic disease, pterygium, following the surgical procedure is perceived as the primary challenge of its management. As the standard procedure, adjuvant therapy of using mitomycin C could dramatically reduce the recurrence of pterygium but could cause multiple serious complications. Our study aimed to investigate curcumin and fibrin glue as alternative candidates for adjuvant therapy in pterygium surgery.

Methods: Human pterygium fibroblast (HPF) was isolated from the patient and cultured in-vitro. The HPF culture was then exposed with mitomycin C (0.4 mg/mL), curcumin (200 μmol/L), and fibrin glue, respectively, for 48 hours. The outcomes were determined by the proliferation of HPF and the expression of transforming growth factor-beta (TGF-β) which were obtained from 2,5-diphenyl-2H-tetrazolium bromide assay and immunofluorescence staining analysis with TGF-β antibody.

Results: The experiment revealed that mitomycin C, curcumin, and fibrin glue could significantly inhibit the proliferation of HPF (p<0.05) suggesting their antifibrotic effect. Further analysis with immunofluorescence staining showed that mitomycin C, curcumin, and fibrin glue could significantly reduce the level of TGF-β as compared with control group (p<0.05).

Conclusion: Mitomycin C was the most potent adjuvant agent to reduce the recurrence of pterygium, followed by curcumin and fibrin glue. Taken altogether, curcumin and fibrin glue have role as adjuvant therapy to prevent recurrence in pterygium surgery.

References

  1. Detorakis. Pathogenetic mechanisms and treatment options for ophthalmic pterygium: Trends and perspectives (Review). Int J Mol Med. 2009;23(4). Available from: http://dx.doi.org/10.3892/ijmm_00000149
  2. Nuzzi R, Tridico F. How to minimize pterygium recurrence rates: clinical perspectives. Clin Ophthalmol. 2018;12:2347–62. Available from: https://pubmed.ncbi.nlm.nih.gov/30538417
  3. Singh G, Wilson MR, Foster CS. Mitomycin Eye Drops as Treatment for Pterygium. Ophthalmology. 1988;95(6):813–21. Available from: http://dx.doi.org/10.1016/s0161-6420(88)33104-0
  4. Hwang S, Choi S. A Comparative Study of Topical Mitomycin C, Cyclosporine, and Bevacizumab after Primary Pterygium Surgery. Korean J Ophthalmol. 2015/11/25. 2015;29(6):375–81. Available from: https://pubmed.ncbi.nlm.nih.gov/26635453
  5. Fonseca EC, Rocha EM, Arruda GV. Comparison among adjuvant treatments for primary pterygium: a network meta-analysis. Br J Ophthalmol. 2017;102(6):748–56. Available from: http://dx.doi.org/10.1136/bjophthalmol-2017-310288
  6. Bianchi E, Scarinci F, Grande C, Plateroti R, Plateroti P, Plateroti AM, et al. Immunohistochemical Profile and VEGF, TGF-β and PGE2 in Human Pterygium and Normal Conjunctiva: Experimental Study and Review of the Literature. Int J Immunopathol Pharmacol. 2012;25(3):607–15. Available from: http://dx.doi.org/10.1177/039463201202500307
  7. Horbelt D, Denkis A, Knaus P. A portrait of Transforming Growth Factor β superfamily signalling: Background matters. Int J Biochem Cell Biol. 2012;44(3):469–74. Available from: http://dx.doi.org/10.1016/j.biocel.2011.12.013
  8. Hu H-H, Chen D-Q, Wang Y-N, Feng Y-L, Cao G, Vaziri ND, et al. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76–83. Available from: http://dx.doi.org/10.1016/j.cbi.2018.07.008
  9. Nakerakanti S, Trojanowska M. The Role of TGF-β Receptors in Fibrosis. Open Rheumatol J. 2012/06/15. 2012;6:156–62. Available from: https://pubmed.ncbi.nlm.nih.gov/22802914
  10. Wanzeler ACV, Barbosa IAF, Duarte B, Borges D, Barbosa EB, Kamiji D, et al. Mechanisms and biomarker candidates in pterygium development. Arq Bras Oftalmol. 2019;82(6). Available from: http://dx.doi.org/10.5935/0004-2749.20190103
  11. Qanita I, Mardhatillah G, Puspita K. Clinical trial evidence on curcumin potential for type 2 diabetes mellitus treatment: A systematic review from 2015-2020. Rasayan J Chem. 2021;Special Issue:126-34.
  12. Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods (Basel, Switzerland). 2017;6(10):92. Available from: https://pubmed.ncbi.nlm.nih.gov/29065496
  13. Radomska-Leśniewska DM, Osiecka-Iwan A, Hyc A, Góźdź A, Dąbrowska AM, Skopiński P. Therapeutic potential of curcumin in eye diseases. Cent J Immunol. 2019/07/30. 2019;44(2):181–9. Available from: https://pubmed.ncbi.nlm.nih.gov/31530988
  14. Song K, Peng S, Sun Z, Li H, Yang R. Curcumin suppresses TGF-β signaling by inhibition of TGIF degradation in scleroderma fibroblasts. Biochem Biophys Res Commun. 2011;411(4):821–5. Available from: http://dx.doi.org/10.1016/j.bbrc.2011.07.044
  15. Panda A, Kumar S, Kumar A, Bansal R, Bhartiya S. Fibrin glue in ophthalmology. Indian J Ophthalmol. 2009;57(5):371–9. Available from: https://pubmed.ncbi.nlm.nih.gov/19700876
  16. Ferris D, Frisbie D, Kisiday J, McIlwraith CW. In vivo healing of meniscal lacerations using bone marrow-derived mesenchymal stem cells and fibrin glue. Stem Cells Int. 2012/01/26. 2012;2012:691605. Available from: https://pubmed.ncbi.nlm.nih.gov/22363348
  17. Komaratih E, Suhendro G, Eddyanto, Purwati, Prakoeswa CR, Rindiastuti Y, et al. Fibrin Glue Maintain Limbal Mesenchymal Stem Cells Survival: A Novel Cell Based Therapy Strategy for Modulating Wound Healing After Trabeculectomy. Saudi J Biomed Res. 2019;4(1):16-22
  18. Tao Y, Chen Q, Zhao C, Yang X, Cun Q, Yang W, et al. The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1. Int J Med Sci. 2020;17(6):734–44. Available from: https://pubmed.ncbi.nlm.nih.gov/32218695
  19. Li D-Q, Lee S-B, Gunja-Smith Z, Liu Y, Solomon A, Meller D, et al. Overexpression of Collagenase (MMP-1) and Stromelysin (MMP-3) by Pterygium Head Fibroblasts. Archives of Ophthalmology. 2001;119(1):71-80.
  20. Zada M, Pattamatta U, White A. Modulation of Fibroblasts in Conjunctival Wound Healing. Ophthalmology. 2018;125(2):179–92. Available from: http://dx.doi.org/10.1016/j.ophtha.2017.08.028
  21. Lee H, Jeong H, Lee CM, Shin J-A, Jang S-W, Lee JH, et al. Antifibrotic Effects of Sakuraso-Saponin in Primary Cultured Pterygium Fibroblasts in Comparison With Mitomycin C. Investig Opthalmology Vis Sci. 2019;60(14):4784. Available from: http://dx.doi.org/10.1167/iovs.19-27153
  22. Chui J, Girolamo N Di, Wakefield D, Coroneo MT. The Pathogenesis of Pterygium: Current Concepts and Their Therapeutic Implications. Ocul Surf. 2008;6(1):24–43. Available from: http://dx.doi.org/10.1016/s1542-0124(12)70103-9
  23. Zhang M, Bian F, Wen C, Hao N. Inhibitory effect of curcumin on proliferation of human pterygium fibroblasts. J Huazhong Univ Sci Technol. 2007;27(3):339–42. Available from: http://dx.doi.org/10.1007/s11596-007-0332-6
  24. Vyas S, Vyas P, Kamdar S. Tissue adhesives in ophthalmology. J Clin Ophthalmol Res. 2013;1(2):107. Available from: http://dx.doi.org/10.4103/2320-3897.112179
  25. Portes KP, de Campos Duprat A, Lancellotti CLP, Silva L, de Souza FC. Influence of selant fibrin on the wound healing of the pigs vocal folds. Braz J Otorhinolaryngol. 2012;78(1):51–6. Available from: http://dx.doi.org/10.1590/s1808-86942012000100008
  26. Vallée A, Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019;9:98. Available from: https://pubmed.ncbi.nlm.nih.gov/31827764
  27. Ng GF, Raihan IS, Azhany Y, Maraina CHC, Banumathi KG, Liza-Sharmini T. Conjunctival TGF-B Level in Primary Augmented Trabeculectomy. Open Ophthalmol J. 2015;9:136–44. Available from: https://pubmed.ncbi.nlm.nih.gov/26401171
  28. Ashrafizadeh M, Zarrabi A, Hushmandi K, Zarrin V, Moghadam ER, Hashemi F, et al. Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review. Front Pharmacol. 2020;11:585413. Available from: https://pubmed.ncbi.nlm.nih.gov/33381035
  29. Brown KD, Shah MH, Liu G-S, Chan EC, Crowston JG, Peshavariya HM. Transforming Growth Factor β1–Induced NADPH Oxidase-4 Expression and Fibrotic Response in Conjunctival Fibroblasts. Investig Opthalmology Vis Sci. 2017;58(7):3011. Available from: http://dx.doi.org/10.1167/iovs.16-20633
  30. Sutyawan E, Niti S, Widiana R. Effect of conjunctiva-limbus transplantation with fibrin glue compare to suture technique on stability of the graft attachment in pterygium surgery. Bali Medical Journal. 2013;2(1):27-32.

How to Cite

Abdurrauf, M., Ramadhan, F., Nurwasis, Zuhria, I., Tambunan, B. A., Notobroto, H. B., Surahman, B., & Komaratih, E. (2022). Mitomycin C, curcumin, and fibrin glue inhibit the cell proliferation and expression of TGF-β in human pterygium fibroblast. Bali Medical Journal, 11(1), 228–233. https://doi.org/10.15562/bmj.v11i1.3315

HTML
0

Total
0

Share

Search Panel